financetom
Business
financetom
/
Business
/
Tolling solutions firm Quarterhill's Q2 revenue misses estimates 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tolling solutions firm Quarterhill's Q2 revenue misses estimates 
Aug 13, 2025 3:52 AM

Overview

* Quarterhill Q2 2025 revenue grows 4% yr/yr, misses analyst expectations

* Net loss for Q2 widens to $6.8 mln, adjusted EBITDA declines

* Company announces restructuring to save $12 mln annually, starting Q3

Outlook

* Quarterhill expects $12 mln annual savings from restructuring starting Q3 2025

* Company renegotiating tolling contracts to reduce costs and enter mediation

* Quarterhill ( QTRHF ) investing in next-gen technology for sustainable profitability

* Company anticipates margin expansion and positive cash flow with strategic plan

Result Drivers

* SAFETY AND ENFORCEMENT - Strong performance in safety and enforcement unit drove revenue growth, per CEO Chuck Myers

* TOLLING CONTRACTS - Cost overruns on tolling projects contributed to decreased gross profit and adjusted EBITDA

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $43.08 $47.90

Revenue mln mln (2

Analysts

)

Q2 Net $6.84

Income mln

Q2 $2.70

Adjusted mln

EBITDA

Q2 Gross $6.34

Profit mln

Q2 $7.44

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the electronic equipment & parts peer group is "buy"

* Wall Street's median 12-month price target for Quarterhill Inc ( QTRHF ) is C$2.00, about 37% above its August 12 closing price of C$1.26

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sierra Leone aims to be West Africa's newest oil and gas exploration frontier
Sierra Leone aims to be West Africa's newest oil and gas exploration frontier
Jun 26, 2025
CAPE TOWN, June 26 (Reuters) - Sierra Leone will wait for the results of a recently-launched offshore 3D seismic survey, its first in over a decade, ahead of potentially opening its next oil and gas licensing round later this year, a senior government official said on Thursday. In partnership with the government's petroleum directorate, consultancy GeoPartners started the six-week seismic...
BHP faces UK contempt charge for funding case over Brazil dam collapse
BHP faces UK contempt charge for funding case over Brazil dam collapse
Jun 26, 2025
LONDON, June 26 (Reuters) - BHP faces a full contempt of court hearing in Britain for funding litigation to try to prevent some Brazilian municipalities suing the mining giant over one of Brazil's worst environmental disasters, London's High Court ruled on Thursday. Thursday's ruling is the latest development in long-running litigation over the collapse in 2015 of the Mariana dam...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution
Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution
Jun 26, 2025
08:37 AM EDT, 06/26/2025 (MT Newswires) -- Altimmune ( ALT ) said Thursday that its phase 2b trial of its product candidate pemvidutide has met its primary endpoint with statistically significant metabolic dysfunction-associated steatohepatitis, or MASH, resolution. The company said pemvidutide showed significant MASH effects and weight loss at 24 weeks. An intent-to-treat analysis showed that MASH resolution without worsening...
Copyright 2023-2026 - www.financetom.com All Rights Reserved